Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atomoxetine/trazodone - Apnimed

Drug Profile

Atomoxetine/trazodone - Apnimed

Alternative Names: AD-504; Trazodone/atomoxetine

Latest Information Update: 23 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apnimed
  • Class Piperazines; Propylamines; Pyridines; Sleep disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Adrenergic uptake inhibitors; Alpha adrenergic receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Sleep apnoea syndrome

Most Recent Events

  • 03 Aug 2022 Apnimed completes a phase-II MARIPOSA clinical trial in Sleep apnoea syndrome (Combination therapy) in USA (PO) (NCT05071612)
  • 02 Jun 2022 Efficacy and adverse events data from a phase II trial in Obstructive sleep apnea released by Apnimed
  • 01 Dec 2021 Phase-II clinical trials in Sleep apnoea syndrome (Combination therapy) in USA (PO) (NCT05071612)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top